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Abstract
Clonal expansion of mast cells carrying the D816V c-kit mutation results in mastocytosis. Recent
studies identified the presence of clonal mast cells carrying this mutation in patients with anaphylaxis
without classic diagnostic findings of systemic mastocytosis.
Introduction and context
Since the description of the first patient with systemic
mastocytosis, the gold standard of diagnosing this
disorder has been the demonstration of increased mast
cells in clusters in tissue biopsies, most commonly of the
bone marrow [1]. Therefore, the term mast cell disease
has been used synonymously with mast cell proliferative
disorders. Patients with systemic mastocytosis not only
have increased mast cells in tissue biopsies but also
have elevated serum levels of tryptase (greater than
20 ng/mL), a mast cell protease used as a surrogate
marker of mast cell burden (Table 1). Molecular
mechanisms resulting in the accumulation of mast cells
in mastocytosis have not been completely elucidated;
however, a gain-of-function mutation in c-kit (D816V) is
found in almost all patients with systemic mastocytosis
[2]. This mutation renders the Kit tyrosine kinase
independent of its ligand stem cell factor, resulting
in constitutive autophosphorylation and activation
of downstream signal transduction cascades. Kit is
expressed in large quantities on mast cell membrane
and functions to induce differentiation and proliferation
of mast cell progenitors, protect them from apoptosis,
and enhance mast cell activation [3].
Recent advances
Patients with mastocytosis are at higher risk for devel-
oping hypotensive episodes resembling anaphylaxis [4].
A recent study estimated the incidence of anaphylaxis
to be as high as 49% in patients with mastocytosis,
representing approximately a 1000-fold increase in
incidence compared with the general population [5].
The most common etiologic factors of anaphylaxis are
drugs, foods, exercise, and Hymenoptera stings. How-
ever, an etiology cannot be identified in a significant
proportion of patients referred to allergists after one or
more episodes of anaphylaxis [6]. These patients are
termed to have idiopathic anaphylaxis. Based on the
observation that mast cell disease is associated with
increased risk of anaphylaxis, patients with unexplained
anaphylaxis have been studied for the presence of
aberrant clonal bone marrow mast cells as seen in
mastocytosis. One study found that 5 out of 12 patients
with recurrent anaphylaxis had aberrant mast cells as
identified by such markers as the c-kit D816V mutation
or the expression of CD25 surface marker [7]. Interest-
ingly, these patients did not have any apparent diag-
nostic evidence of a proliferative mast cell disease such
as clusters of mast cells in bone marrow or urticaria
pigmentosa skin lesions. The demonstration of aberrant
mast cells in these patients required sensitive techniques
of flow cytometry or mutation analysis of enriched mast
cells. Thus, these patients presented with a disorder
characterized primarily by activation rather than prolifera-
tion of mast cells, despite carrying the same c-kit mutation
in systemic mastocytosis. Such patients who lack major
diagnostic criteria ofmastocytosis(multifocal aggregatesof
mast cells in tissue biopsies) but who are detected to have
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expression, or morphologic abnormalities such as spindle
shapes and hypogranulation) are termed to have ‘mono-
clonal mast cell activationsyndrome’ (MMAS) [8,9]. Some
patients with MMAS have normal or only slightly elevated
serum tryptase levels, making it especially challenging to
diagnose a mast cell disorder. From the hematopoietic
clonal standpoint, this nomenclature is perhaps analogous
tomonoclonalgammapathyofundeterminedsignificance,
which represents a plasma cell disorder with a limited
clonal expansion. Follow-up of these patients so far has
suggested that most do not progress to systemic mastocy-
tosis (personal observation).
Recent studies examined the role of mast cell clonality
in patients who experience anaphylaxis after Hymen-
optera stings [10]. In a study examining 379 patients
with systemic reactions to Hymenoptera stings, it
was found that approximately 12% have elevated base-
line tryptase levels [11]. Approximately 62% of
these patients with elevated tryptase levels satisfied the
criteria for systemic mastocytosis, whereas 26.5% had
MMAS. The incidence of clonal mast cell disease in
patients who experience anaphylaxis to other triggers
such as drugs and foods has also been investigated and
found to be approximately 1.5%, while 6.6% of this
population had elevated tryptase levels [12]. Clinical
analysis of symptomatic presentation of patients with
clonal mast cell disease showed that they suffered
significantly more hypotensive episodes in the absence
of urticaria as compared with patients with true idio-
pathic anaphylaxis [13].
Implications for clinical practice
Based on these recent findings, we recommend the
investigation of occult or overt mast cell disease in
all patients with recurrent hypotensive anaphylaxis
episodes, especially those with idiopathic anaphylaxis
and Hymenoptera sensitivity. A baseline tryptase level
should be obtained at a minimum in addition to
the usual workup to determine an allergic etiology.
Patients with elevated baseline tryptase levels should
be referred to a specialized center to have clonal mast
cell disease investigated.
Clinical management of patients with clonal mast cell
disease includes symptomatic therapy with antimediator
medications such as antihistamines, antileukotriene
medications, glucocorticoids, and cromolyn individua-
lized for each patient. Self-injectable epinephrine should
be considered for every patient due to the increased risk
of anaphylaxis. Patients with a history of Hymenoptera
anaphylaxis should be referred to an allergist for eva-
luation of IgE-mediated sensitization. If found to have
allergic Hymenoptera sensitization, patients with clonal
mast cell disease are candidates for lifelong Hymenoptera
venom immunotherapy.
Abbreviation
MMAS, monoclonal mast cell activation syndrome.
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Table 1. Diagnostic criteria for systemic mastocytosis
Major
Multifocal clusters of 15 or more mast cells in a biopsy of tissue such as bone marrow
Minor
1. Serum baseline tryptase of greater than 20 ng/mL
2. Aberrant expression of CD25 or CD2 or both on mast cells
3. Presence of a codon 816 mutation (most commonly D816V) in peripheral blood or a lesional tissue
4. Morphologic abnormalities of bone marrow mast cells (spindle shapes, hypogranulation, or bilobated or multilobated nuclei)
Either one major and one minor or three minor criteria are needed to make a diagnosis of systemic mastocytosis.
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